If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"false","IpdInfoTypeIcf":"false","IpdInfoTypeCsr":"false","IpdInfoTypeProtocol":"false","IpdInfoTypeSap":"false","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"No","acronym":"","allocation":"","arm_groups":[{"arm_group_label":"Participants receiving Otilimab","arm_group_description":"","arm_type":""},{"arm_group_label":"Participants receiving Standard of care (SoC)","arm_group_description":"","arm_type":""},{"arm_group_label":"Participants receiving placebo","arm_group_description":"","arm_type":""},{"arm_group_label":"Participants receiving comparator","arm_group_description":"","arm_type":""}],"assignment":"","brief_summary":"The aim of this observational study is to conduct a systematic literature review (SLR) and indirect treatment comparison (ITC) to assess the comparative effectiveness of Otilimab to other competitor products among hospitalized participants with severe pulmonary COVID-19 related disease.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Systemic literature review and indirect treatment comparison of Otilimab for Coronavirus Disease 2019 (COVID-19)","conditions":[{"DisplayValue":"Unmapped","DisplayValue_OneLinkTx":"","InternalValue":"CON_UNMAPPED","LookupValue":"COVID-19","LookupValue_OneLinkTx":""}],"created_date":"04/06/2026 14:22:33","criteria":"Inclusion Criteria:\n - Adult participants greater than or equal to (>=)18 years of age\n - Positive SARS-CoV-2 result (any validated test)\n - Hospitalized due to COVID-19 illness\n - Developing new onset of oxygenation impairment requiring respiratory support (including, but not limited to, high flow oxygen, non-invasive ventilation, or mechanical ventilation).\n\nExclusion Criteria:\n - Participants less than (<) 18 years of age\n - Negative SARS-CoV-2 test\n - Not hospitalized due to COVID-19 illness.","detailed_description":"NA","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"N/A","display_phase_internal":"PHASE_NA","display_status":"Ongoing","display_status_internal":"RECSTATUS_O_ONGOING","endpoint":"","enrollment":"0","exclusion":"","gender":"All","gender_based":"No","gender_description":"","healthy_volunteers":"No","id":"ac1564d6-dad8-5014-b0c2-f038b00aadf3","internal":{"content":null,"contentDigest":"c5c449aadb84b12828e14f5dbd982c23","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria:\n - Adult participants greater than or equal to (>=)18 years of age\n - Positive SARS-CoV-2 result (any validated test)\n - Hospitalized due to COVID-19 illness\n - Developing new onset of oxygenation impairment requiring respiratory support (including, but not limited to, high flow oxygen, non-invasive ventilation, or mechanical ventilation).\n\nExclusion Criteria:\n - Participants less than (<) 18 years of age\n - Negative SARS-CoV-2 test\n - Not hospitalized due to COVID-19 illness.","interventions":[],"interventional_subtype":"Treatment","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":["Otilimab","COVID-19","Systematic literature review","Indirect treatment comparison","Observational"],"last_follow_up_date":"10/29/2021 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"NA","maximum_age":"NA","minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"04/06/2026 14:22:33","number_of_arms":"","observational_design":{"biospecimen_description":"NA","biospecimen_retention":"None Retained","number_of_groups":"4","observational_study_design":"Cohort","patient_registry":"false","target_duration_quantity":"","target_duration_units":"","timing":"Retrospective"},"official_title":"Systematic Literature Review and Indirect Treatment Comparison of Otilimab for Hospitalized Patients with Severe Pulmonary COVID-19 related Disease","org_study_id":"ViiV214537","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Active, not recruiting - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"No","fda_regulated_drug":"No","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"N/A","primary_compl_date":"10/29/2021 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Percentage of participants alive and free of respiratory failure","outcome_time_frame":"Up to 60 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Percentage of participants recovered from respiratory failure","outcome_time_frame":"Up to 60 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Percentage of deceased participants due to all causes","outcome_time_frame":"Up to 60 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Percentage of participants alive and independent of supplementary oxygen","outcome_time_frame":"Up to 60 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Percentage of participants admitted to the intensive care unit (ICU)","outcome_time_frame":"Up to 60 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to final ICU discharge","outcome_time_frame":"Up to 60 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to final hospital discharge","outcome_time_frame":"Up to 60 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to number of deaths due to all causes","outcome_time_frame":"Up to 60 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to recovery from respiratory failure","outcome_time_frame":"Up to 60 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to last dependence on supplementary oxygen","outcome_time_frame":"Up to 60 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Percentage of participants with adverse events (AEs)/serious adverse events (SAEs)","outcome_time_frame":"Up to 60 days","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"","outcome_time_frame":"","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["NA"]},"start_date":"03/06/2021 00:00:00","study_type":"Observational","therapeutic_area":"","citations":[],"is_section_801":null}},"pageContext":{"studyId":"ViiV214537"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}